Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series

Academic Article


  • Infertility and subfertility are commonly faced by females with cystic fibrosis (FwCF) and resulting in decreased contraceptive use and increased utilization of reproductive technologies. Elexacaftor-tezacaftor-ivacaftor (ETI) is a CFTR modulator that affects common causes of subfertility. Two CF centers conducted a retrospective chart review on females with CF who were receiving ETI and became pregnant. We analyzed obstetrical-gynecological history, genotype, and clinical response to ETI therapy. Fourteen FwCF on ETI became pregnant. Half (7) of the FwCFs were previously attempting to conceive, but only three were using contraceptives. Four FwCF had a history of infertility; two were reconsidering use of reproductive technologies (IUI). Patients achieved conception at mean 8 weeks after initiating ETI. ETI may lessen CF-associated factors that affect fertility; however, its exact mechanism is unknown. This warrants counseling on contraceptive use and family planning prior to initiation of therapy and at routine intervals while utilizing ETI.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • O'Connor KE; Goodwin DL; NeSmith A; Garcia B; Mingora C; Ladores SL; Rowe SM; Krick S; Solomon GM
  • Start Page

  • 399
  • End Page

  • 401
  • Volume

  • 20
  • Issue

  • 3